Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis

Bibliography

• BROCKBANK J, SCHENTAG CT, ROSEN Get al.: Psoriatic arthritis (PsA) is common among patients with psoriasis and family medicine clinic attendees [abstract]. Arthritis Rheum. (2001) 44:S94 (Abstract 249).
   Google Scholar
• GLADMAN D: Psoriatic arthritis. In: Word Textbook of Rheumatology. 3rd edition. Isenberg DA, Maddison PJ, Woo P, Glass DN, Breedveld F (Eds), Oxford University Press, Oxford, UK (2004):6.4.4.
   Google Scholar
• SALVARANI C, LO SG, MACCHIONI P et al: Prevalence of psoriatic arthritis in Italian psoriatic patients. J. Rheumatol (1995) 22:1499–1503.
   PubMed Web of Science ®Google Scholar
• SHBEEB M, URAMOTO KM, GIBSON LE, O'FALLON WM, GABRIEL SE: The epidemiology of psoriatic arthritis in Olmstead County, Minnesota, USA, 1982–1991.1 Rheumatol (2000) 27:1247–1250.
   Google Scholar
• GLADMAN DD, SHUCKETT R, RUSSELL ML, THORNE JC, SCHACHTER RK: Psoriatic arthritis (PSA)—an analysis of 220 patients. Q. J. Med. (1987) 62:127–141.
   PubMedGoogle Scholar
• TORRE ALONSO JC, RODRIGUEZ PA, ARRIBAS CASTRILLO JM, BALLINO GARCIA J, RIESTRA NORIEGA JL, LOPEZ LARREA C: Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br. J. Rheumatol. (1991) 30:245–250.
   PubMedGoogle Scholar
• WONG K, GLADMAN DD, HUSTED J, LONG JA, FAREWELL VT: Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. (1997) 40:1868–1872.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, FAREWELL VT, WONG K, HUSTED J: Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. (1998) 41:1103–1110.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, BROCKBANK J: Psoriatic arthritis. Expert Opin. Invest. Drugs (2000) 9:1511–1522.
   PubMed Web of Science ®Google Scholar
• OFFIDANI A, CELLINIA, VALERI G, GIOVAGNONI A: Subclinical joint involvement in psoriasis: magnetic resonance imaging and X-ray findings. Acta Derm. Venereol (1998) 78:463–465.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, STAFFORD-BRADY F, CHANG CH, LESANDOWSKI K, RUSSELL ML: Longitudinal study of clinical and radiological progression in psoriatic arthritis. J. Rheumatol (1990) 17:809–812.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, ANTONI CE: Treating psoriatic arthritis: how effective are TNF antagonists? Arthritis Res. Ther. (2004) 6\(Suppl. 2):531–535.
   Google Scholar
• MEASE P, GOFFE BS: Diagnosis and treatment of psoriatic arthritis. J. Am. Acad. Dermatol (2005) 52:1–19.
   PubMed Web of Science ®Google Scholar
• MEASE P: Targeting therapy in psoriatic arthritis. Drug Discov. Today (2004) 1:389–396.
   Google Scholar
• •A comprehensive review of traditional and newer therapies for the treatment of PsA.
   Google Scholar
• MEASE PJ: Recent advances in the management of psoriatic arthritis. Curr. Opin. Rheumatol (2004) 16:366–370.
   PubMed Web of Science ®Google Scholar
• JONES G, CROTTY M, BROOKS P: Interventions for treating psoriatic arthritis (Cochrane Methodology Review). In: The Cochrane Library. Issue 4. John Wiley & Sons, Ltd., Chichester, UK (2003).
   Google Scholar
• •Meta-analysis evaluating double-blind, placebo-controlled studies of various pharmacological agents in PsA.
   Google Scholar
• ABU-SHAKRA M, GLADMAN DD, THORNE JC, LONG J, GOUGH J, FAREWELL VT: Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J. Rheumatol (1995) 9:241–245.
   Google Scholar
• MADER R, GLADMAN DD, LONG J, GOUGH J, FAREWELL VT: Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin. Invest. Med. (1995) 18:139–143.
   Web of Science ®Google Scholar
• UJFALUSSY I, KOO E, SESZTAK M, GERGELY P: Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis: a comparative study of 270 cases. Z. Rheumatol. (2003) 62:155–160.
   PubMed Web of Science ®Google Scholar
• WHITING O KEEFE QE, FYE KH, SACK KD: Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am. J. Med. (1991) 90:711–716.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, GOFFE BS, METZ J et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet (2000) 356:385–390.
   PubMed Web of Science ®Google Scholar
• •This clinical trial was the first large-scale trial to demonstrate the efficacy and safety of etanercept in PsA.
   Google Scholar
• MEASE P, GOFFE BS, METZ J, VANDERSTOEP A: Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis [abstract]. Ann. Rheum. Dis. (2001) 60\(Suppl. 1):146.
   Google Scholar
• •Results demonstrating the efficacy of etanercept in PsA after 24 weeks of therapy.
   Google Scholar
• MEASE PJ, KIVITZ AJ, BURGH FX et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. (2004) 50:2264–2272.
   PubMed Web of Science ®Google Scholar
• •Pivotal trial evaluating the efficacy of etanercept in the management of PsA.
   Google Scholar
• MEASE PJ, RUDERMAN EM, RITCHLIN C, ORY P, TSUJI W: Etanercept in psoriatic arthritis: sustained improvement in joint and skin disease and inhibition of radiographic progression at 2 years [abstract]. Ann. Rheum. Dis. (2004) 63\(Suppl. 1):99 (Abstract OP0136).
   Google Scholar
• •This study demonstrates the long-term ability of etanercept to inhibit disease progression in patients with PsA.
   Google Scholar
• ANTONI CE, KAVANAUGH A, KIRKHAM B et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis. Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. (2005) 52:1227–1236.
   PubMedGoogle Scholar
• •This article describes results from the first large-scale trial of infliximab in patients with PsA.
   Google Scholar
• ANTONI C, KRUEGER GG, DE VLAM K et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. (2005) 64:1158–1164.
   Google Scholar
• •An article describing the primary results of the IMPACT 2 trial, a large-scale trial of infliximab in PsA.
   Google Scholar
• ANTONI CE, KAVANAUGH A, GLADMAN D et al.: The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year [abstract]. Ann. Rheum. Dis. (2005) 64(Suppl. III [3]):Abstract OP0156.
   Google Scholar
• •This clinical trial demonstrated the ability of infliximab to inhibit disease progression long-term in patients with PsA.
   Google Scholar
• VAN DER HEIJDE D, KAVANAUGH A, BEUTLER A et al.: Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: results from IMPACT 2 trial [abstract]. Ann. Rheum. Dis. (2005) 64(Suppl. III [3]):Abstract OP0169.
   Google Scholar
• •This large-scale study of infliximab in PsA demonstrated inhibition of disease progression.
   Google Scholar
• MEASE PJ: TNFa therapy in psoriatic arthritis and psoriasis. How and why does it work? Ann. Rheum. Dis. (2004) 63:755–758.
   PubMed Web of Science ®Google Scholar
• •This article provides a comprehensive review of the mechanism of TNF-a therapy in PsA.
   Google Scholar
• VEALE DJ, RITCHLIN C, FITZGERALD O: Immunopathology of psoriasis and psoriatic arthritis. Ann. Rheum. Dis. (2005) 64\(Suppl. 2):ii26-ii29.
   Google Scholar
• •This article provides an in-depth review of the immunopathology of PsA, with specific focus on the role of TNF-a.
   Google Scholar
• MEASE PJ: Tumour necrosis factor (TNF)in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann. Rheum. Dis. (2002) 61:298–304.
   PubMed Web of Science ®Google Scholar
• ETTEHADI P, GREAVES MW, WALLACH D, ADERKA D, CAMP RD: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin. Exp. Immunol (1994) 96:146–151.
   PubMed Web of Science ®Google Scholar
• PARTSCH G, STEINER G, LEEB BF et al.: Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol. (1997) 24:518–523.
   PubMed Web of Science ®Google Scholar
• COOPER WO, FAVA RA, GATES CA, CREMER MA, TOWNES AS: Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin. Exp. Immunol (1992) 89:244–250.
   PubMed Web of Science ®Google Scholar
• •This experimental model provided important evidence of the central role of TNF in the acceleration of inflammation in inflammatory arthritis.
   Google Scholar
• WILLIAMS RO, FELDMANN M, MIANI RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA (1992) 89:974–978.
   Google Scholar
• •This experimental model provided important evidence of the central role of anti-TNF antibodies in decreasing inflammation in inflammatory arthritis.
   Google Scholar
• SALFELD J, KAYMAKCALAN Z, TRACEY D, ROBERTS A, KAMEN R: Generation of fully human anti-TNF antibody D2E7 [abstract]. Arthritis Rheum. (1998) 41(Suppl.):557.
   Google Scholar
• DEN BROEDER AA, JOOSTEN LA, SAXNE T et al.: Long term anti-tumour necrosis factor a monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis. (2002) 61:311–318.
   PubMed Web of Science ®Google Scholar
• BARRERA P, JOOSTEN LA, DEN BROEDER AA et al.: Effects of treatment with a fully human anti-tumour necrosis factor a monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFa in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2001) 60:660–669.
   Google Scholar
• KAVANAUGH A, GREENWALD M, ZIZIC T et al.: Immune response is not affected by adalimumab therapy [abstract]. Ann. Rheum. Dis. (2003) 62\(Suppl. 1):169 (Poster THU0196).
   Google Scholar
• GRANNEMAN RG, ZHANG Y, NOETERSHEUSER PA et al.: Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (Humiram, Abbott) in rheumatoid arthritis (RA) patients during Phase II/III clinical trials [abstract]. Arthritis Rheum. (2003) 48(9)(Suppl.):S140 (Poster 256).
   Google Scholar
• AWNI WM, CASCELLA P, OLEKA N et al.: Steady-state pharmacokinetics (PK) of adalimumab (Humiram, Abbott) following 40 mg subcutaneous (se) injection every other week (eow) in rheumatoid arthritis (RA) patients with and without methotrexate (MTX) background therapy [abstract]. Arthritis Rheum. (2003) 48(9)(Suppl.):S140 (Poster 255).
   Google Scholar
• AWNI WM, CASCELLA P, OLEKA N et al.: Steady-state adalimumab (HumiraTm) pharmacokinetics (PK) following every other week (eow) dosing of 40 mg subcutaneous (se) injection, in rheumatoid arthritis (RA) patients treated with and without concomitant methotrexate (MTX) [abstract]. Rheumatology (2004) 43\(Suppl. 2):ii40 (Abstract 39).
   Google Scholar
• VELAGAPUDI RB, NOERTERSHEUER PA, AWNI WM et al.: Effect of methotrexate (MTX) coadministration on the pharmacokinetics (PK) of adalimumab (Humiram, Abbott) following a single intravenous (iv) injection [abstract]. Arthritis Rheum. (2003) 48(9)(Suppl.):S141 (Poster 258).
   Google Scholar
• RITCHLIN C, ANADARAJAHA A, TOTTERMAN S et al.: Preliminary data from a study of adalimumab in the treatment of psoriatic arthritis [abstract]. Ann. Rheum. Dis. (2004) 63(Suppl. I):403 (Poster SAT0054).
   Google Scholar
• CARLIN CS, FELDMAN SR, KRUEGER JG, MENTER A, KRUEGER GG: A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J. Am. Acad. Dermatol (2004) 50:859–866.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, GLADMAN D, RITCHLIN C et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Results of a double-blind, randomized, placebo-controlled trial. The ADEPT study group. Arthritis Rheum. (2005) 52:3279–3289.
   PubMed Web of Science ®Google Scholar
• ••This placebo-controlled, double-blindstudy identifies adalimumab as an effective and well-tolerated treatment for patients with PsA who have failed NSAIDs. Adalimumab improved the signs and symptoms of PsA, as well as measures of disability, quality of life and disease progression.
   Google Scholar
• MEASE PJ, SHARP JT, ORY P et al.: Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: results from ADEPT. Ann. Rheum. Dis. (2005) 64(Suppl. III [3]):Abstract FRI0212.
   Google Scholar
• ••This subanalysis of ADEPT demonstratesthe efficacy of adalimumab in retarding disease progression up to 48 weeks.
   Google Scholar
• MEASE PJ, GANGULY R, WANKE L, YU E, SINGH A: How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) group guidelines [abstract]. Ann. Rheum. Dis. (2004) 63\(Suppl. 1):Poster SAT0015.
   Google Scholar
• GLADMAN DD, MEASE PJ, EMERY P, WELLBORNE F, COMBE B, WEINBERG MA: Adalimumab treatment effects on quality of life in patients with psoriatic arthritis: results from ADEPT. Ann. Rheum. Dis. (2005) 64(Suppl. III [3]):Abstract FRI0203.
   Google Scholar
• GENOVESE MC, MEASE PJ, THOMSON GT, KIVITZ AJ, PERDOK RJ, WEINBERG MA: Adalimumab efficacy in patients with psoriatic arthritis who failed prior DMARD therapy [abstract]. Ann. Rheum. Dis. (2005) 64(Suppl. III [3]):Abstract FRI0187.
   Google Scholar
• ••This placebo-controlled, double-blindstudy evaluates adalimumab in patients with PsA who have failed DMARDs. Adalimumab improved skin and joint symptoms, as well as measures of disability.
   Google Scholar
• MENTER MA, GORDON K, LEONARDI C, CHEN D: Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis [abstract]. J. Am. Acad. Dermatol (2005) 52(3 Suppl.):174 (Poster P2713).
   Google Scholar
• WALLACE KL, LANGLEY R, BISSONNETTE R, MELLULI L, HOFFMAN R: Quality of life in patients with psoriatic arthritis treated with adalimumab: subanalysis of studies in moderate to severe psoriasis [abstract]. J. Am. Acad. Dermatol. (2005) 52(3 Suppl.):192 (Poster P2783).
   Google Scholar
• KHILJI FA, GONZALEZ M, FINLAY AY: Clinical meaning of change in Dermatology Life Quality Index scores. Br. J. Dermatol. (2002) 147\(Suppl. 62):50.
   Google Scholar
• LANGLEY R, LEONARDI C, TOTH D et al.: Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis [abstract]. J. Am. Acad. Dermatol. (2005) 52(3 Suppl.):2 (Poster P8).
   Google Scholar
• SCHIFF MH, KAVANAUGH AF, WEISMAN M et al.: Safety and efficacy of more than 4 years of adalimumab therapy in rheumatoid arthritis [abstract]. J. Am. Acad. Dermatol. (2005) 52(3 Suppl.):203 (Poster P2825).
   Google Scholar
• SCHIFF MH, BURMESTER GR, KENT J et al.: Safety of adalimumab in long-term treatment of patients with rheumatoid arthritis [abstract]. J. Am. Acad. Dermatol. (2005) 52(3 Suppl.):203 (Poster P286).
   Google Scholar
• WELLS AF, KUPPER H, FISCHKOFF S et al.: Injection-site reactions in adalimumab rheumatoid arthritis (RA) pivotal clinical trials [abstract]. Ann. Rheum. Dis. (2003) 62(Suppl. I):411 (Abstract AB0166).
   Google Scholar
• MEASE P: TNF-a inhibitors in psoriatic arthritis. In: Psoriasis and Psoriatic Arthritis: An Integrated Approach. Gordon KB, Ruderman EM (Eds), Springer-Verlag, Heidelberg, Germany (2005):223–234.
   Google Scholar
• SCHIFF M, VAN DE PUTTE LB, BREEDVELD FC et al.: Rates of infection in adalimumab rheumatoid arthritis clinical trials [abstract]. Ann. Rheum. Dis. (2003) 62(Suppl. I):184 (Poster THU0246).
   Google Scholar
• SCHIFF MH, CHARTASH E, SPENCER-GREEN G: Malignancies in rheumatoid arthritis (RA) clinical trials with adalimumab (HUMIRA(D) [abstract]. Arthritis Rheum. (2003) 48(9 Suppl.):S700 (Abstract 1832).
   Google Scholar
• STRAND V, CHARTASH E, SENGUPTA N et al.: Improvement in health-related quality of life, health utility, and fatigue in patients with active rheumatoid arthritis (RA) on adalimumab (HUMIRA(D) therapy [abstract]. Arthritis Rheum. (2003) 48(9)(Suppl.):S402 (Poster 991).
   Google Scholar
• WALLACE KL, GORDON KB, LANGLEY M et al.: Dermatologic quality of life in patients with moderate to severe plaque psoriasis receiving 48 weeks of adalimumab therapy [abstract]. J. Am. Acad. Dermatol (2005) 52(3 Suppl.):180 (Poster P2734).
   Google Scholar
• WALLACE KL, BISSONNETTE R, LEONARDI C et al.: Effects of adalimumab on health status as measured by EQ-5D in patients with moderate to severe plaque psoriasis [abstract]. J. Am. Acad. Dermatol (2005) 52(3 Suppl.):181 (Poster P2741).
   Google Scholar
• WALLACE KL, LEONARDI C, KEMPERS S et al.: General physical and mental health status in patients with moderate to severe plaque psoriasis receiving 48 weeks of adalimumab therapy [abstract]. J. Am. Acad. Dermatol (2005) 52(3 Suppl.):185 (Poster P2757).
   Google Scholar
• MEASE PJ, GLADMAN DD, KRUEGER GG: Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Ann. Rheum. Dis. (2005) 64:1-2. Websites
   Google Scholar
• http://www.psoriasis.org/news/stories/ 2001 /200104_npfsurvey.php National Psoriasis Foundation: Survey: what people with psoriasis are saying (2001).
   Google Scholar
• http://www.emedicine.com/derm/ topic918.htm Voorhes AV Fadeyi DW: Psoriatic arthritis (2004).
   Google Scholar